The diagnostic and prognostic values of microRNA-196a in cancer

Abstract

MicroRNA-196a (miR-196a) was previously reported to be up-regulated in cancers, and it has the diagnostic and prognostic values in cancers. Whereas, the conclusion was still unclear according to the published data. To assess such roles of miR-196a in cancers, the present study was conducted based on published data and online cancer-related databases. To identify the relevant published data, we searched articles in databases and then the relevant data were extracted to evaluate the correlation between miR-196a expression and diagnosis, prognosis for cancer patients. The pooled results showed that miR-196a was a valuable diagnostic biomarker in cancer (area under curve (AUC) = 0.87, 95% CI: 0.84–0.90; sensitivity (SEN) = 0.73, 95% CI: 0.64–0.81; specificity (SPE) = 0.90, 95% CI: 0.81–0.95), which was consistent with the data from databases (breast cancer: miR-196a-3p: AUC = 0.77, 95% CI: 0.74–0.79; miR-196a-5p: AUC = 0.71, 95% CI: 0.66–0.75; pancreatic cancer: miR-196a-3p: AUC = 0.80, 95% CI: 0.73–0.87; miR-196a-5p: AUC = 0.61, 95% CI: 0.51–0.71). In addition, the pooled result revealed that elevated miR-196a expression in tumor tissues (HR = 2.54, 95% CI: 1.79–3.61, PHeterogeneity=0.000, I2 = 75.8%) or serum/plasma (HR = 4.06, 95% CI: 2.67–6.18, PHeterogeneity=0.668, I2 = 0%) of patients was an unfavorable survival biomarker, which was consistent with the data from databases (adrenocortical carcinoma: HR = 5.70; esophageal carcinoma: HR = 1.93; brain lower grade glioma: HR = 2.91; GSE40267: HR = 2.47, 95% CI: 1.2–5.07; TCGA: HR = 1.82, 95% CI: 1.21–2.74; GSE19783: HR = 4.24, 95% CI: 1–18.06). In short, our results demonstrated that miR-196a in tumor tissue or serum/plasma could be used as a prognostic and diagnostic values for cancers.

A Photoresponsive and Metal–Organic Framework Encapsulated DNA Tetrahedral Entropy-Driven Amplifier for High-Performance Imaging Intracellular MicroRNA

“…Apart from this, we also discover that the average Cy3 emission of A549 cells is ∼1.4-fold higher than that of the HeLa cells. The recovery in different types of cancer cells is likely ascribed to the high-abundance nature of miRNA-196a in lung tissue-related tumors, and such a content trend agrees well with the reverse transcription-polymerase chain reaction (RT-PCR) data (Figure S20). Furthermore, the imaging accuracies are confirmed by the flow cytometry analysis (Figure S19B), among which faultless consistence between these different detection means is presented.…”

“…In light of the potential role of miRNA-196a in the development of lung tumors, establishing an assay method with favorable sensitivity and specificity to precisely measure the intracellular levels at various physiological states can provide meaningful information for clinical diagnosis. 40 To this end, the A549 cells are treated with two forms of frequently used biochemical regulation reagents (250 nM miRNA mimic and 250 nM inhibitor), and the sensing of intracellular targets is further accomplished. As shown in Figure S21A, in comparison with the control cells (without any treatments, middle images), a dramatic signal enhancement is detected in the up-regulation group (top images), while the fluorescence intensity appears as a certain decline phenomenon for the down-regulating manner (bottom images).…”

“…In light of the potential role of miRNA-196a in the development of lung tumors, establishing an assay method with favorable sensitivity and specificity to precisely measure the intracellular levels at various physiological states can provide meaningful information for clinical diagnosis . To this end, the A549 cells are treated with two forms of frequently used biochemical regulation reagents (250 nM miRNA mimic and 250 nM inhibitor), and the sensing of intracellular targets is further accomplished.…”

Predictive and Prognostic Value of Non-Coding RNA in Breast Cancer

“…Moreover, the pooled analysis revealed that elevated miR-196a levels in tumor tissues (HR = 2.54, 95% CI: 1.79–3.61, P Heterogeneity = 0.000, I 2 = 75.8%) or serum and plasma (HR = 4.06, 95% CI: 2.67–6.18, P Heterogeneity = 0.668, I 2 = 0%) correlated with unfavorable survival. In conclusion, tumor tissue or blood-derived miR-196a could be used a prognostic and diagnostic biomarker for cancers such as BC [ 77 ]. Another meta-analysis reported that miR-206 plays an important role in cancers and it could be used as a prognostic biomarker.…”

How to Differentiate Benign from Malignant Adrenocortical Tumors?

“…Results have been inconclusive on other micro-RNAs [123,131]. Deregulated expression of several micro-RNAs was not only associated with ACC diagnosis but also with prognosis [114,124,132,133]. The diagnostic accuracy of micro-RNAs is shown to be variable [134].…”